- Home
- CTNM
CTNM
Contineum Therapeutics Inc. Class A Common Stock
as 04-25-2025 4:00pm EST
Stocks
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | N/A | IPO Year: | 2024 |
| Target Price: | $24.80 | AVG Volume (30 days): | 83.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.85 - $22.00 | Next Earning Date: | 05-16-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Contineum Therapeutics Inc. Class A Common Stock News
CTNM Breaking Stock News: Dive into CTNM Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
We're Not Very Worried About Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Rate
Business Wire
a month ago
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Simply Wall St.
a month ago
Institutional investors in Contineum Therapeutics, Inc. (NASDAQ:CTNM) have had a wonderful week after share price increased 24%
Business Wire
a month ago
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Business Wire
2 months ago
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Business Wire
2 months ago
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
Business Wire
2 months ago
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Business Wire
4 months ago
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Compare CTNM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CTNM Contineum Therapeutics Inc. Class A Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.